True Wealth Design’s Arcus Biosciences RCUS Stock Holding History

True Wealth Design’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-126	Closed	-$990	–	2781
2025 Q1	$990	Buy	+126	New	+$1.46K	﹤0.01%	1270

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

True Wealth Design's RCUS Position: Q2 2025 in Review

True Wealth Design sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 126 shares — an estimated $990 sold.

True Wealth Design first reported a position in RCUS in Q1 2025 and held it in 1 quarter. The position peaked at $990 in Q1 2025. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

True Wealth Design reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
True Wealth Design sold 126 Arcus Biosciences shares in Q2 2025, an estimated $990.
True Wealth Design first reported a position in Arcus Biosciences in Q1 2025 and held it in 1 quarter.
True Wealth Design's Arcus Biosciences position peaked at $990 in Q1 2025.
185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on True Wealth Design's 13F filing for Q2 2025, filed 6 Aug 2025.